covid19. covid19
Conditions
Interventions
Intervention 1: Intervention group 1: This group of patients with Covid19 who have received standard treatments ,receive tocilizumab brand name ACTEMRA and TEMZIVA from ROCHE PHARMA and ARIOGEN PHARME
Sponsors
Shahre-kord University of Medical Sciences
Eligibility
Sex/Gender
All
Age
25 Years to 70 Years
Inclusion criteria
Inclusion criteria: People with Covid 19 (based on RT-PCR test for SARS-CoV-19 virus or CT scan criteria) People between the ages of 25 and 70 Symptoms indicate severe disease (more than 50% of lung involvement in CT or oxygen saturation below 90% or respiratory rate greater than 30 per minute) Elevated CRP, ferritin and other inflammatory markers
Exclusion criteria
Exclusion criteria: People who test positive for PPD, HCV, HBV and have infections other than Covid 19 infection Pregnancy and pregnancy intention Mild involvement or in the early stages of Covid 19
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ferritin. Timepoint: Before the intervention and five days after receiving the drug. Method of measurement: Elisa.;D-dimer. Timepoint: Before the intervention and five days after receiving the drug. Method of measurement: Bio-Lis.;C-Reactive Protein. Timepoint: Before the intervention and five days after receiving the drug. Method of measurement: Bio-Lis.;Lactate Dehydrogenase. Timepoint: Before the intervention and five days after receiving the drug. Method of measurement: Bio-Lis.;Complete blood count. Timepoint: Before the intervention and five days after receiving the drug. Method of measurement: sysmex.;Erythrocyte Sedimentation Rate. Timepoint: Before the intervention and five days after receiving the drug. Method of measurement: Sediman Reader. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAmir hossein Koohi
Shahre-kord University of Medical Sciences
Outcome results
None listed